Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin liposomal - PARI Pharma

Drug Profile

Ciclosporin liposomal - PARI Pharma

Alternative Names: Ciclosporin inhalation - PARI Pharma; Cyclosporine A Inhalation - PARI Pharma; L-CsA - PARI Pharma; L-CsA-i

Latest Information Update: 26 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PARI
  • Developer Breath Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiolitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchiolitis obliterans

Most Recent Events

  • 07 Oct 2019 Breath Therapeutics plans the phase II BOSTON-4 trial for Bronchiolitis Obliterans following allogeneic hematopoietic stem cell transplant in France, Germany and Spain in January 2020 (Inhalation) (NCT04107675)
  • 31 Jul 2019 Breath Therapeutics plans the phase III BOSTON-3 trial for Bronchiolitis Obliterans in February 2020 (Inhalation, Aerosol) (NCT04039347)
  • 25 Jul 2019 Breath Therapeutics has been acquired by Zambon Company SpA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top